Locations:
Min Investment:
Max Investment:
Target Investment:
Doctor of Philosophy - PhD, Experimental Biology and Biomedicine
(2015 - 2019)
2024
2023 - 2024
2017 - 2023
2020 - 2023
- Investigating the role of epigenetic alterations in a mouse genome responsible for the early onset of age-related phenotypes and related diseases
2017 - 2019
- Investigating a novel mechanism by which small molecules activate SIRT1 and how they can be used to treat aging and age-related metabolic diseases
2021 - 2022
2021 - 2022
- Performed scientific and investment diligence on biotech companies across multiple therapeutic areas - Contributed to multiple investment memos highlighting the investment thesis of prospective companies, including technical, regulatory, market, financial and intellectual property analysis - Performed deal sourcing by engaging with companies' management teams through introductory calls and investment conferences
2020 - 2021
2020 - 2021
- Prepared risk analyses and mitigation/diligence plans to evaluate early-stage investment opportunities in mitochondria physiology - Identified and prioritize potential programs for pre-seed and seed-stage through in-depth literature review, KOL engagement, and risk analyses
2019 - 2019
2019 - 2019
- Assessed commercial opportunities for a vectored antibody delivery technology developed in the Balazs Lab at The Ragon Institute - Identified and defined the TPP for target disease indications, assessed IP, evaluated go-to-market strategy for different indications, defined the regulatory strategy
2013 - 2014
2013 - 2014
- Studied the impact of mitochondria dysfunction pre-synaptic nerve terminals in an in vitro model of Alzheimer's disease